Targeting IgE to facilitate oral immunotherapy for food allergy: a potential new role for anti-IgE therapy?

References

• Prescott SL, Pawankar R, Allen KJ, et al. A global survey of. changing patterns of food allergy burden in children. World Allergy Organ J 2013;6:21
   PubMedGoogle Scholar
• Sicherer SH, Sampson HA. Food allergy: epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol 2014;133:291-307; quiz 308
   PubMed Web of Science ®Google Scholar
• Brown EM, Arrieta MC, Finlay BB. A fresh look at the hygiene hypothesis: how intestinal microbial exposure drives immune effector responses in atopic disease. Semin Immunol 2013;25:378-87
   Google Scholar
• Umetsu D, McIntire J, Macaubas C, et al. Asthma: an epidemic of dysregulated immunity. Nat Immunol 2002;3:715-20
   PubMed Web of Science ®Google Scholar
• Cao S, Feehley TJ, Nagler CR. The role of commensal bacteria in the regulation of sensitization to food allergens. FEBS Lett 2014. [ Epub ahead of print]
   Google Scholar
• Khoriaty E, Umetsu DT. Oral immunotherapy for food allergy: towards a new horizon. Allergy Asthma Immunol Res 2013;5:3-15
   PubMed Web of Science ®Google Scholar
• Anagnostou K, Islam S, King Y, et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet 2014;383:1297-304
   PubMed Web of Science ®Google Scholar
• Gupta R, Holdford D, Bilaver L, et al. The economic impact of childhood food allergy in the United States. JAMA Pediatr 2013;167:1026-31
   PubMed Web of Science ®Google Scholar
• Keet CA, Wood RA. Emerging therapies for food allergy. J Clin Invest 2014;124:1880-6
   PubMed Web of Science ®Google Scholar
• Senti G, von Moos S, Tay F, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol 2012;129:128-35
   PubMed Web of Science ®Google Scholar
• Larenas-Linnemann D, Blaiss M, Van Bever HP, et al. Pediatric sublingual immunotherapy efficacy: evidence analysis, 2009-2012. Ann Allergy Asthma Immunol 2013;110:402-15; e409
   PubMed Web of Science ®Google Scholar
• Meglio P, Giampietro PG, Carello R, et al. Oral food desensitization in children with IgE-mediated hen’s egg allergy: a new protocol with raw hen’s egg. Pediatr Allergy Immunol 2013;24:75-83
   PubMed Web of Science ®Google Scholar
• Vazquez-Ortiz M, Alvaro-Lozano M, Alsina L, et al. Safety and predictors of adverse events during oral immunotherapy for milk allergy: severity of reaction at oral challenge, specific IgE and prick test. Clin Exp Allergy 2013;43:92-102
   PubMed Web of Science ®Google Scholar
• Anagnostou K, Clark A, King Y, et al. Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome. Clin Exp Allergy 2011;41:1273-81
   PubMed Web of Science ®Google Scholar
• Brozek JL, Terracciano L, Hsu J, et al. Oral immunotherapy for IgE-mediated cow’s milk allergy: a systematic review and meta-analysis. Clin Exp Allergy 2012;42:363-74
   PubMed Web of Science ®Google Scholar
• Nurmatov U, Venderbosch I, Devereux G, et al. Allergen-specific oral immunotherapy for peanut allergy. Cochrane Database Syst Rev 2012;9:CD009014
   Google Scholar
• Ho MH, Wong WH, Chang C. Clinical spectrum of food allergies: a comprehensive review. Clin Rev Allergy Immunol 2014;46:225-40
   PubMed Web of Science ®Google Scholar
• Leung DY, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003;348:986-93
   PubMed Web of Science ®Google Scholar
• Sampson HA, Leung DY, Burks AW, et al. A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 2011;127:1309-10; e1301
   PubMed Web of Science ®Google Scholar
• Savage JH, Courneya JP, Sterba PM, et al. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol 2012;130:1123-9; e1122
   PubMed Web of Science ®Google Scholar
• Nadeau K, Schneider L, Hoyte E, et al. Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol 2011;127:1722-4
   Google Scholar
• Schneider LC, Rachid R, LeBovidge J, et al. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol 2013;132:1368-74
   PubMed Web of Science ®Google Scholar
• Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol 2012;129:448-55
   PubMed Web of Science ®Google Scholar
• Burks AW, Jones SM, Wood RA, et al. Oral immunotherapy for treatment of egg allergy in children. N Engl J Med 2012;367:233-43
   PubMed Web of Science ®Google Scholar
• Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial (PRROTECT). Available from: http://clinicaltrials.gov/show/NCT01781637
   Google Scholar
• Varshney P, Steele PH, Vickery BP, et al. Adverse reactions during peanut oral immunotherapy home dosing. J Allergy Clin Immunol 2009;124:1351-2
   PubMed Web of Science ®Google Scholar
• Begin P, Dominguez T, Wilson SP, et al. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Allergy Asthma Clin Immunol 2014;10:7
   PubMed Web of Science ®Google Scholar